Analysts Set ICU Medical, Inc. (NASDAQ:ICUI) Price Target at $172.00

ICU Medical, Inc. (NASDAQ:ICUI) has earned a consensus rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $172.00.

ICUI has been the subject of a number of research analyst reports. KeyCorp lifted their price objective on shares of ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday. Needham & Company LLC raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research report on Wednesday, May 27th. Sanford C. Bernstein cut shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Zacks Research raised shares of ICU Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Finally, Piper Sandler decreased their price target on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th.

ICU Medical Stock Performance

Shares of ICUI opened at $157.44 on Wednesday. The stock has a market capitalization of $3.93 billion, a price-to-earnings ratio of 85.10, a PEG ratio of 2.14 and a beta of 0.76. ICU Medical has a 12 month low of $107.00 and a 12 month high of $162.85. The firm has a fifty day simple moving average of $144.21 and a 200 day simple moving average of $139.74. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, beating the consensus estimate of $1.78 by $0.19. The firm had revenue of $525.77 million during the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business’s quarterly revenue was down 12.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Research analysts forecast that ICU Medical will post 6.51 EPS for the current fiscal year.

Insider Activity at ICU Medical

In other news, Director David C. Greenberg sold 2,424 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the sale, the director owned 7,960 shares in the company, valued at $978,363.60. The trade was a 23.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. The trade was a 11.17% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Norges Bank acquired a new position in shares of ICU Medical during the 4th quarter worth $58,083,000. Kirr Marbach & Co. LLC IN boosted its stake in ICU Medical by 18.4% in the first quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock valued at $5,702,000 after buying an additional 6,863 shares in the last quarter. F m Investments LLC grew its position in ICU Medical by 33.3% in the fourth quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock valued at $6,637,000 after acquiring an additional 11,608 shares during the last quarter. Thrivent Financial for Lutherans grew its position in ICU Medical by 1,604.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock valued at $43,294,000 after acquiring an additional 285,648 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in ICU Medical by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock valued at $387,313,000 after acquiring an additional 89,755 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.